Truist Securities Reiterates Buy on Amgen, Maintains $320 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Amgen (NASDAQ:AMGN) and maintained a price target of $320.
November 29, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst reaffirms a Buy rating on Amgen with a $320 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating by a prominent analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price. The maintained price target of $320 suggests a level of confidence in the company's future performance and may reinforce investor optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100